ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

DA-5218

A development code. Also written as “DA-5218-C”.

Its studies are mostly in Diabetes Mellitus, led by Dong-A ST.

Furthest: phase 4, since Nov 13, 20252 company-led studies, 1 open or runningNext primary completion: Nov 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dong-A ST21 open or runningphase 4since Nov 13, 2025Jul 4, 2022Nov 2027phase 4 · NCT07229534

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 4, 2022First study: phase 1 study in HealthyFirst studyNCT05449704 · 90 enrolled · Korea, Republic of
  2. Nov 13, 2025Phase 4 study in Diabetes MellitusNCT07229534 · 238 planned

Ahead

  1. Nov 2027Primary completion: phase 4 study in Diabetes MellitusNCT07229534

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07229534Diabetes Mellitus4Not yet recruitingNov 2027238
NCT05449704Healthy · Korea, Republic of1UNKNOWNSep 3, 202290

How it is read

Names in the registry

  • “DA-5218”, 2 entries
  • “DA-5218-C”, 1 entry

Codes read as this program: DA5218.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.